JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$0.25
-0.03 (-9.81%)
▼
5d:
+4.63%
30d:
-37.72%
90d:
-44.59%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called JUNS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JUNS shows positive signals but monitor for confirmation. Market pricing in 25.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: JUNS shows positive signals but monitor for confirmation. Market pricing in 25.7% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $0.25, which is considered oversold relative to its 30-day fair value range of $0.26 to $0.37. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.2) compared to its historical average (10.2). Remarkably, the market is currently pricing in an annual earnings decline of 25.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.17, while resistance sits at $0.53. Short-term momentum is weak, with the stock down 9.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+11852.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.17, while resistance sits at $0.53. Short-term momentum is weak, with the stock down 9.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+11852.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.26 -
$0.37
Company Quality Score
48/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
70.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-9.8%)
- BULLISH: Trading 11852.2% below Wall St target ($30.00)
Trading Range Analysis
30-Day Trading Range
$0.26 -
$0.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.17
Resistance Level
$0.53
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.18
Wall Street Target
$30.00
(+11852.2%)
Valuation Discount vs History
-25.7% cheaper
PE vs Historical
4.2 vs 10.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-25.7%
(market-implied from PE analysis)
1-Year Target
$0.23
(-10%)
2-Year Target
$0.20
(-19%)
3-Year Target
$0.18
(-27%)
3-Yr Target (if PE normalizes)
(PE: 4→10)
$0.45
(+78%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.2 to 10.2
Stabilization Target:
$0.61
(+143.8%)
PE Expansion Potential:
+143.8%
Share & Embed Analysis
Last updated: June 03, 2026 10:27 PM ET
Data refreshes hourly during market hours. Next update: 11:27 PM
Data refreshes hourly during market hours. Next update: 11:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 66 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 55 HOLD |
